To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link

The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:
 Type of Product
 HPAPIs
 Highly Potent Finished Dosage Forms

 Company Size
 Small-sized
 Mid-sized
 Large / Very Large

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Type of Pharmacological Molecule
 Small Molecules
 Biologics

 Type of Highly Potent Finished Dosage Form
 Injectables
 Oral Solids
 Creams
 Others

 Key geographical regions
 North America
 Europe
 Asia Pacific
 Rest of the World

The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030” report features the following companies, which we identified to be key players in this domain:
 AbbVie Contract Manufacturing
 CARBOGEN AMCIS
 Catalent
 Evonik
 Formosa Laboratories
 Intas
 Lonza
 MabPlex
 Pfizer CentreOne

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Competitive Analysis

6. HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles

7. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles

8. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles

9. Partnerships and Collaborations

10. Recent Expansions

11. Capacity Analysis

12. Market Sizing and Opportunity Analysis

13. Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates

14. Concluding Remarks

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]